389 related articles for article (PubMed ID: 12630645)
1. Lipodystrophy, insulin resistance, diabetes mellitus, dyslipidemia, and cardiovascular disease in human immunodeficiency virus infection.
Tanwani LK; Mokshagundam SL
South Med J; 2003 Feb; 96(2):180-8; quiz 189. PubMed ID: 12630645
[TBL] [Abstract][Full Text] [Related]
2. [Metabolic alterations in HIV-associated lipodystrophy syndrome].
Valente AM; Reis AF; Machado DM; Succi RC; Chacra AR
Arq Bras Endocrinol Metabol; 2005 Dec; 49(6):871-81. PubMed ID: 16544008
[TBL] [Abstract][Full Text] [Related]
3. Cardiovascular risk and body-fat abnormalities in HIV-infected adults.
Grinspoon S; Carr A
N Engl J Med; 2005 Jan; 352(1):48-62. PubMed ID: 15635112
[No Abstract] [Full Text] [Related]
4. Metabolic effects of protease inhibitor therapy.
Bernasconi E
AIDS Read; 1999 Jul; 9(4):254-6, 259-60, 266-9. PubMed ID: 12737115
[TBL] [Abstract][Full Text] [Related]
5. Clinical review 153: Lipodystrophy in human immunodeficiency virus-infected patients.
Chen D; Misra A; Garg A
J Clin Endocrinol Metab; 2002 Nov; 87(11):4845-56. PubMed ID: 12414837
[TBL] [Abstract][Full Text] [Related]
6. Metabolic complications in HIV infection. In search of underlying mechanisms.
Johnson DL
Adv Nurse Pract; 2002 Jul; 10(7):45-50, 76. PubMed ID: 12420551
[No Abstract] [Full Text] [Related]
7. HIV-associated lipodystrophy: pathogenesis, prognosis, treatment, and controversies.
Koutkia P; Grinspoon S
Annu Rev Med; 2004; 55():303-17. PubMed ID: 14746523
[TBL] [Abstract][Full Text] [Related]
8. Lipodystrophy syndrome: the morphologic and metabolic effects of antiretroviral therapy in HIV infection.
Norris A; Dreher HM
J Assoc Nurses AIDS Care; 2004; 15(6):46-64. PubMed ID: 15538016
[TBL] [Abstract][Full Text] [Related]
9. Therapy insight: Body-shape changes and metabolic complications associated with HIV and highly active antiretroviral therapy.
Falutz J
Nat Clin Pract Endocrinol Metab; 2007 Sep; 3(9):651-61. PubMed ID: 17710086
[TBL] [Abstract][Full Text] [Related]
10. Adipocytes targets and actors in the pathogenesis of HIV-associated lipodystrophy and metabolic alterations.
Gougeon ML; Pénicaud L; Fromenty B; Leclercq P; Viard JP; Capeau J
Antivir Ther; 2004 Apr; 9(2):161-77. PubMed ID: 15134178
[TBL] [Abstract][Full Text] [Related]
11. Diabetes, insulin resistance and dyslipidaemia in lipodystrophic HIV-infected patients on highly active antiretroviral therapy (HAART).
Vigouroux C; Gharakhanian S; Salhi Y; Nguyen TH; Chevenne D; Capeau J; Rozenbaum W
Diabetes Metab; 1999 Sep; 25(3):225-32. PubMed ID: 10499191
[TBL] [Abstract][Full Text] [Related]
12. Dyslipidaemia and cardiovascular risk in HIV infection.
Kulasekaram R; Peters BS; Wierzbicki AS
Curr Med Res Opin; 2005 Nov; 21(11):1717-25. PubMed ID: 16307691
[TBL] [Abstract][Full Text] [Related]
13. HIV lipodystrophy and its metabolic consequences: implications for clinical practice.
Wierzbicki AS; Purdon SD; Hardman TC; Kulasegaram R; Peters BS
Curr Med Res Opin; 2008 Mar; 24(3):609-24. PubMed ID: 18208641
[TBL] [Abstract][Full Text] [Related]
14. [HIV infection, antiretroviral therapy, and endothelium].
Hürlimann D; Weber R; Enseleit F; Lüscher TF
Herz; 2005 Sep; 30(6):472-80. PubMed ID: 16170677
[TBL] [Abstract][Full Text] [Related]
15. Influence of rosiglitazone on flow-mediated dilation and other markers of cardiovascular risk in HIV-infected patients with lipoatrophy.
Kovacic JC; Martin A; Carey D; Wand H; Mallon PW; Feneley MP; Emery S; Cooper DA; Carr A;
Antivir Ther; 2005; 10(1):135-43. PubMed ID: 15751771
[TBL] [Abstract][Full Text] [Related]
16. [Lipodystrophy and lipid metabolism alterations in HIV-infected patients receiving highly active antiretroviral therapy (HAART)].
Calza L; Manfredi R; Chiodo F
Recenti Prog Med; 2004 May; 95(5):265-75. PubMed ID: 15202680
[TBL] [Abstract][Full Text] [Related]
17. Metabolic abnormalities and cardiovascular disease risk factors in adults with human immunodeficiency virus infection and lipodystrophy.
Hadigan C; Meigs JB; Corcoran C; Rietschel P; Piecuch S; Basgoz N; Davis B; Sax P; Stanley T; Wilson PW; D'Agostino RB; Grinspoon S
Clin Infect Dis; 2001 Jan; 32(1):130-9. PubMed ID: 11118392
[TBL] [Abstract][Full Text] [Related]
18. Disorders of glucose metabolism in patients infected with human immunodeficiency virus.
Dubé MP
Clin Infect Dis; 2000 Dec; 31(6):1467-75. PubMed ID: 11096014
[TBL] [Abstract][Full Text] [Related]
19. Antiretroviral therapy with heart.
Randell P; Moyle G
Am J Ther; 2009; 16(6):579-84. PubMed ID: 19940610
[TBL] [Abstract][Full Text] [Related]
20. Metabolic syndrome and cardiovascular disease in patients with human immunodeficiency virus.
Grinspoon SK
Am J Med; 2005 Apr; 118 Suppl 2():23S-28S. PubMed ID: 15903292
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
